Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

By sjmartinez • February 19, 2025

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID: 39967197.

Tags: breast cancer, Electronic health records, Geriatric oncology, Hematology/Oncology, Outcomes, Publications, Risk factor, Treatment, women’s oncology

Access to AlloTx for AML: the value of the social phenotype

Schiller G. Access to AlloTx for AML: the value of the social phenotype. Blood. 2025 Jun 19;145(25):2941-2942. doi: 10.1182/blood.2025028826. PMID: 40536784.

Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality in Vital Statistics

Bor J, Bird M, Hakes JK, Himmelstein DU, Himmelstein G, Woolhandler S. Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality[...]

Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report and Literature Review

Tai JW, Roufeh EN, Reed JP. Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report[...]